Opendata, web and dolomites

EHVA SIGNED

European HIV Vaccine Alliance (EHVA): a EU platform for the discovery and evaluation of novel prophylactic and therapeutic vaccine candidates

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "EHVA" data sheet

The following table provides information about the project.

Coordinator
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE 

Organization address
address: RUE DE TOLBIAC 101
city: PARIS
postcode: 75654
website: www.inserm.fr

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Project website http://www.ehv-a.eu/
 Total cost 28˙135˙596 €
 EC max contribution 22˙188˙521 € (79%)
 Programme 1. H2020-EU.3.1.2. (Preventing disease)
 Code Call H2020-PHC-2015-single-stage_RTD
 Funding Scheme RIA
 Starting year 2016
 Duration (year-month-day) from 2016-01-01   to  2020-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE FR (PARIS) coordinator 3˙914˙527.00
2    UNIVERSITY COLLEGE LONDON UK (LONDON) participant 2˙514˙226.00
3    INTERNATIONAL AIDS VACCINE INITIATIVE INC US (NEW YORK) participant 1˙927˙436.00
4    STICHTING BIOMEDICAL PRIMATE RESEARCH CENTER NL (RIJSWIJK ZH) participant 1˙000˙017.00
5    HEINRICH-PETTE INSTITUT LEIBNIZ INSTITUT FUER EXPERIMENTELLE VIROLOGIE DE (HAMBURG) participant 992˙500.00
6    FIT BIOTECH OY FI (Tampere) participant 965˙190.00
7    IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE UK (LONDON) participant 916˙600.00
8    CONSORCI INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER ES (BARCELONA) participant 915˙038.00
9    UNIVERSITAET REGENSBURG DE (REGENSBURG) participant 915˙000.00
10    COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES FR (PARIS 15) participant 707˙842.00
11    ISTITUTO SUPERIORE DI SANITA IT (ROMA) participant 643˙625.00
12    UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF DE (HAMBURG) participant 616˙500.00
13    UNIVERSITE GRENOBLE ALPES FR (SAINT MARTIN D'HERES) participant 567˙637.00
14    THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD UK (OXFORD) participant 564˙977.00
15    CHELSEA AND WESTMINSTER HOSPITAL NHS FOUNDATION TRUST UK (LONDON) participant 516˙901.00
16    MEDIZINISCHE UNIVERSITAT INNSBRUCK AT (INNSBRUCK) participant 515˙000.00
17    KAROLINSKA INSTITUTET SE (STOCKHOLM) participant 508˙246.00
18    INSERM TRANSFERT SA FR (PARIS) participant 452˙000.00
19    AGENCIA ESTATAL CONSEJO SUPERIOR DEINVESTIGACIONES CIENTIFICAS ES (MADRID) participant 414˙973.00
20    ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM NL (AMSTERDAM) participant 414˙937.00
21    LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN DE (MUENCHEN) participant 365˙000.00
22    FRED HUTCHINSON CANCER RESEARCH CENTER NON PROFIT CORPORATION US (SEATTLE WA) participant 350˙000.00
23    ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM NL (ROTTERDAM) participant 310˙000.00
24    THE UNIVERSITY OF LIVERPOOL UK (LIVERPOOL) participant 299˙999.00
25    ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE LAZZARO SPALLANZANI-ISTITUTO DI RICOVERO E CURA A CARATTERE SCIENTIFICO IT (ROMA) participant 249˙963.00
26    VRIJE UNIVERSITEIT BRUSSEL BE (BRUSSEL) participant 149˙950.00
27    THE GENERAL HOSPITAL CORPORATION US (BOSTON MA) participant 100˙000.00
28    STICHTING INTERNATIONAL AIDS VACCINE INITIATIVE THE NETHERLANDS NL (AMSTERDAM) participant 90˙601.00
29    SANOFI PASTEUR SA FR (LYON) participant 85˙000.00
30    JANSSEN VACCINES & PREVENTION BV NL (LEIDEN) participant 84˙845.00
31    EUROPEAN AIDS TREATMENT GROUP EV DE (DUSSELDORF) participant 50˙000.00
32    UGANDA NATIONAL HEALTH RESEARCH ORGANISATION UG (ENTEBBE) participant 24˙985.00
33    ASSOCIATION PAC-CI CI (ABIDJAN) participant 15˙000.00
34    Instituto Nacional de Saúde MZ (Maputo) participant 15˙000.00
35    NATIONAL INSTITUTE FOR MEDICAL RESEARCH TZ (DAR ES SALAAM) participant 15˙000.00
36    CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS CH (LAUSANNE) participant 0.00
37    EUROVACC FOUNDATION CH (LAUSANNE) participant 0.00
38    FONDAZIONE PER L ISTITUTO DI RICERCA IN BIOMEDICINA CH (BELLINZONA) participant 0.00
39    HOSPITAL CLINICO Y PROVINCIAL DE BARCELONA ES (BARCELONA) participant 0.00
40    UNIVERSITAET BERN CH (BERN) participant 0.00
41    UNIVERSITAT ZURICH CH (ZURICH) participant 0.00
42    UNIVERSITE DE LAUSANNE CH (LAUSANNE) participant 0.00
43    UNIVERSITE JOSEPH FOURIER GRENOBLE 1 FR (GRENOBLE) participant 0.00

Map

 Project objective

Many HIV vaccine concepts and several efficacy trials have been conducted in the prophylactic and therapeutic fields with limited success. There is an urgent need to develop better vaccines and tools predictive of immunogenicity and of correlates of protection at early stage of vaccine development to mitigate the risks of failure. To address these complex and challenging scientific issues, the European HIV Vaccine Alliance (EHVA) program will develop a Multidisciplinary Vaccine Platform (MVP) in the fields of prophylactic and therapeutic HIV vaccines. The Specific Objectives of the MVP are to build up: 1.Discovery Platform with the goal of generating novel vaccine candidates inducing potent neutralizing and non-neutralizing antibody responses and T-cell responses, 2. Immune Profiling Platform with the goal of ranking novel and existing (benchmark) vaccine candidates on the basis of the immune profile, 3. Data Management/Integration/Down-Selection Platform, with the goal of providing statistical tools for the analysis and interpretation of complex data and algorithms for the efficient selection of vaccines, and 4. Clinical Trials Platform with the goal of accelerating the clinical development of novel vaccines and the early prediction of vaccine failure. EHVA project has developed a global and innovative strategy which includes: a) the multidisciplinary expertise involving immunologists, virologists, structural biology experts, statisticians and computational scientists and clinicians; b) the most innovative technologies to profile immune response and virus reservoir; c) the access to large cohort studies bringing together top European clinical scientists/centres in the fields of prophylactic and therapeutic vaccines, d) the access to a panel of experimental HIV vaccines under clinical development that will be used as benchmark, and e) the liaison to a number of African leading scientists/programs which will foster the testing of future EHVA vaccines through EDCTP

 Deliverables

List of deliverables.
Draft EHVA dissemination and exploitation plan Websites, patent fillings, videos etc. 2019-11-27 17:18:40
EHVA website and branding launched Websites, patent fillings, videos etc. 2019-11-27 17:18:40
First EHVA newsletter and fact sheet developed and published Websites, patent fillings, videos etc. 2019-11-27 17:18:40

Take a look to the deliverables list in detail:  detailed list of EHVA deliverables.

 Publications

year authors and title journal last update
List of publications.
2019 Melanie Wittner, Veronika Schlicker, Jana Libera, Jan-Hendrik Bockmann, Thomas Horvatits, Oliver Seiz, Silke Kummer, Carolin F. Manthey, Anja Hüfner, Marcus Kantowski, Thomas Rösch, Olaf Degen, Samuel Huber, Johanna M. Eberhard, Julian Schulze zur Wiesch
Comparison of the integrin α4β7 expression pattern of memory T cell subsets in HIV infection and ulcerative colitis
published pages: e0220008, ISSN: 1932-6203, DOI: 10.1371/journal.pone.0220008
PLOS ONE 14/7 2020-03-05
2019 Beatriz Perdiguero, Cristina Sánchez-Corzo, Carlos Sorzano, Lidia Saiz, Pilar Mediavilla, Mariano Esteban, Carmen Gómez
A Novel MVA-Based HIV Vaccine Candidate (MVA-gp145-GPN) Co-Expressing Clade C Membrane-Bound Trimeric gp145 Env and Gag-Induced Virus-Like Particles (VLPs) Triggered Broad and Multifunctional HIV-1-Specific T Cell and Antibody Responses
published pages: 160, ISSN: 1999-4915, DOI: 10.3390/v11020160
Viruses 11/2 2020-03-05
2019 Yuka Nadai, Kathrin Held, Sarah Joseph, Mohamed I. M. Ahmed, Verena S. Hoffmann, David Peterhoff, Marco Missanga, Asli Bauer, Agricola Joachim, Ulf Reimer, Johannes Zerweck, Sheena McCormack, Alethea V. Cope, Roger Tatoud, Robin J. Shattock, Merlin Lee Robb, Eric G. Sandstroem, Michael Hoelscher, Leonard Maboko, Muhammad Bakari, Arne Kroidl, Ralf Wagner, Jonathan Weber, Georgios Pollakis, Christof
Envelope-Specific Recognition Patterns of HIV Vaccine-Induced IgG Antibodies Are Linked to Immunogen Structure and Sequence
published pages: , ISSN: 1664-3224, DOI: 10.3389/fimmu.2019.00717
Frontiers in Immunology 10 2020-03-05
2019 Beatriz Perdiguero, Carmen Elena Gómez, Juan García-Arriaza, Cristina Sánchez-Corzo, Carlos Óscar S. Sorzano, Sarah Wilmschen, Dorothee von Laer, Benedikt Asbach, Christina Schmalzl, David Peterhoff, Song Ding, Ralf Wagner, Janine Kimpel, Yves Levy, Giuseppe Pantaleo, Mariano Esteban
Heterologous Combination of VSV-GP and NYVAC Vectors Expressing HIV-1 Trimeric gp145 Env as Vaccination Strategy to Induce Balanced B and T Cell Immune Responses
published pages: , ISSN: 1664-3224, DOI: 10.3389/fimmu.2019.02941
Frontiers in Immunology 10 2020-03-05
2019 Sarah Wilmschen, Joern E. Schmitz, Janine Kimpel
Viral Vectors for the Induction of Broadly Neutralizing Antibodies against HIV
published pages: 119, ISSN: 2076-393X, DOI: 10.3390/vaccines7030119
Vaccines 7/3 2020-03-05
2019 Suresh C. Raman, Ernesto Mejías-Pérez, Carmen E. Gomez, Juan García-Arriaza, Beatriz Perdiguero, Aneesh Vijayan, Mar Pérez-Ruiz, Ana Cuervo, César Santiago, Carlos Oscar S. Sorzano, Cristina Sánchez-Corzo, Christiane Moog, Judith A. Burger, Anna Schorcht, Rogier W. Sanders, José L. Carrascosa, Mariano Esteban
The Envelope-Based Fusion Antigen GP120C14K Forming Hexamer-Like Structures Triggers T Cell and Neutralizing Antibody Responses Against HIV-1
published pages: , ISSN: 1664-3224, DOI: 10.3389/fimmu.2019.02793
Frontiers in Immunology 10 2020-03-05
2019 Patricia Pérez, María Q. Marín, Adrián Lázaro-Frías, Carlos Óscar S. Sorzano, Mauro Di Pilato, Carmen E. Gómez, Mariano Esteban, Juan García-Arriaza
An MVA Vector Expressing HIV-1 Envelope under the Control of a Potent Vaccinia Virus Promoter as a Promising Strategy in HIV/AIDS Vaccine Design
published pages: 208, ISSN: 2076-393X, DOI: 10.3390/vaccines7040208
Vaccines 7/4 2020-03-05
2019 C. Bresk, Tamara Hofer, Sarah Wilmschen, Marina Krismer, Anja Beierfuß, Grégory Effantin, Winfried Weissenhorn, Michael Hogan, Andrea Jordan, Rebecca Gelman, David Montefiori, Hua-Xin Liao, Joern Schmitz, Barton Haynes, Dorothee von Laer, Janine Kimpel
Induction of Tier 1 HIV Neutralizing Antibodies by Envelope Trimers Incorporated into a Replication Competent Vesicular Stomatitis Virus Vector
published pages: 159, ISSN: 1999-4915, DOI: 10.3390/v11020159
Viruses 11/2 2020-03-05
2017 Peterhoff D, Wagner R
Guiding the long way to neutralization
published pages: , ISSN: 1746-630X, DOI:
Current Oppinion in HIV and AIDS 2019-11-27
2016 Benjamin Zimmer, Veronika Grassmann, Tim-Henrik Bruun, Thomas Schubert, Anna Gabele, Alexander Kliche and Ralf Wagner
Identification of novel HIV-1 vaccine candidates using mammalian cell-surface display and FACS panning
published pages: , ISSN: , DOI:
2019-11-27
2016 Kliche A., Koop J., Ziegler C., Peterhoff D., Asbach B., Schütz A., Schmid V. and Wagner R
Identification and characterization of trimer stabilized HIV envelope protein
published pages: , ISSN: , DOI:
2019-11-27
2018 Ralf Wagner, Benedikt Asbach
Dürfen wir noch auf eine HIV-Impfung hoffen?
published pages: 24-27, ISSN: 1438-3276, DOI: 10.1007/s15006-018-0649-z
MMW - Fortschritte der Medizin 160/S2 2019-11-27
2017 Ralf Wagner
Effective HIV vaccine – Narrow path to broadly neutralizing antibodies (editorial)
published pages: , ISSN: , DOI:
2019-11-27
2017 Max Medina-Ramírez, Rogier W. Sanders, Quentin J. Sattentau
Stabilized HIV-1 envelope glycoprotein trimers for vaccine use
published pages: 1, ISSN: 1746-630X, DOI: 10.1097/COH.0000000000000363
Current Opinion in HIV and AIDS 2019-11-27
2017 Ralf Wagner
Effective HIV vaccine
published pages: 191-194, ISSN: 1746-630X, DOI: 10.1097/coh.0000000000000371
Current Opinion in HIV and AIDS 12/3 2019-11-27
2017 David Peterhoff, Alexandra Hauser, Iris Ganser, Ralf Wagner
Structure guided molecular engineering of stable C-clade Env trimer scaffolds for vaccine design
published pages: , ISSN: , DOI:
2019-11-27
2017 David Peterhoff, Ralf Wagner
Guiding the long way to broad HIV neutralization
published pages: 257-264, ISSN: 1746-630X, DOI: 10.1097/coh.0000000000000356
Current Opinion in HIV and AIDS 12/3 2019-11-27
2016 Glögl M., Schmid V.,  Kliche A., Peterhoff D. and Wagner R
Generation of HIV-1 new envelope immunogens with optimized antigenicity profiles
published pages: , ISSN: , DOI:
2019-11-27
2017 Benedikt Asbach, Ralf Wagner
Particle-based delivery of the HIV envelope protein
published pages: 265-271, ISSN: 1746-630X, DOI: 10.1097/coh.0000000000000366
Current Opinion in HIV and AIDS 12/3 2019-11-27
2016 Carolina Beltrán Pavez , Amanda Fabra García , Alberto Merino , Christian Brander, Josep M. Gatell, Felipe García Eloísa Yuste and Víctor Sánchez-Merino
Induction of MPER responses by immunization with Virus-Like Particles (VLPs) carrying a BroadlyNeutralizing Antibody-selected HIV-1 Envelope
published pages: , ISSN: , DOI:
2019-11-27
2017 Asbach B, Wagner R
Particle-based delivery of the HIV envelope protein
published pages: , ISSN: 1746-630X, DOI:
Current Oppinion in HIV and AIDS 2019-11-27

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EHVA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EHVA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.2.)

ECRC (2019)

Developing a diverse portfolio of vaccine candidates for Rift Valley Fever, Chikungunya and Ebola

Read More  

EMPOWER (2020)

European platforM to PromOte Wellbeing and HEalth in the woRkplace

Read More  

ONCOBIOME (2019)

Gut OncoMicrobiome Signatures (GOMS) associated with cancer incidence, prognosis and prediction of treatment response.

Read More